加载中
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
收盘时
US$1.26
−US$0.22 · -14.86%
盘中时间采用ET。市场数据可能有所延迟。
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
日内区间
当前US$1.26
52周区间
当前US$1.26
盘中时间采用ET。市场数据可能有所延迟。
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
日内区间
当前US$1.26
52周区间
当前US$1.26
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5.42万 USD | 256.68万 USD | 284.18万 USD | 672.21万 USD | — |
| 销货成本 | 4.34万 USD | 160.74万 USD | 228.14万 USD | 413.57万 USD | — |
| 毛利 | 1.08万 USD | 95.94万 USD | 56.04万 USD | 258.64万 USD | — |
| 研究与开发 | 544.29万 USD | 638.9万 USD | 767.63万 USD | 933.84万 USD | 817.36万 USD |
| 销售、一般及管理费用 | 770.13万 USD | 2194.52万 USD | 1308.44万 USD | 798.83万 USD | 530.22万 USD |
| 营业费用 | 1126.81万 USD | 3043.91万 USD | 2627.75万 USD | 1766.52万 USD | 1336.78万 USD |
| 利息收入 | — | — | — | — | 50.54万 USD |
| 利息支出 | 125.03万 USD | 115.84万 USD | 28.3万 USD | 12.67万 USD | — |
| 折旧和摊销 | 104.18万 USD | 118.44万 USD | 113.52万 USD | 71.79万 USD | 54.36万 USD |
| 营业利润 | −1125.73万 USD | −2947.97万 USD | −2571.72万 USD | −1507.88万 USD | −1336.78万 USD |
| 净利润 | −795.97万 USD | −3002.38万 USD | −2499.43万 USD | −1490.07万 USD | −1286.25万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅3项
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
